{"id":1006560,"date":"2026-09-29T10:13:08","date_gmt":"2026-09-29T14:13:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/"},"modified":"2026-09-29T10:13:08","modified_gmt":"2026-09-29T14:13:08","slug":"keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/","title":{"rendered":"Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda"},"content":{"rendered":"<div class=\"mw_release\">\n<p>LEXINGTON, Mass., Sept.  29, 2026  (GLOBE NEWSWIRE) &#8212; Keros Therapeutics, Inc. (\u201cKeros\u201d) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (\u201cTGF-\u00df\u201d) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis (\u201cMF\u201d) and anemia on concurrent ruxolitinib therapy.<\/p>\n<p>\u201cThe milestone marks another important step forward for the elritercept program,\u201d said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. \u201cWe are grateful to our partner Takeda for their dedication to bringing this important potential new treatment to patients in need.\u201d<\/p>\n<p>Under the terms of the global license agreement with Takeda to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau, which became effective on January 16, 2025, Keros received a $200 million upfront cash payment in February 2025, and is eligible to receive development, commercial and sales milestones with the potential to exceed $1.1 billion. Keros will also be eligible to receive tiered royalties on net sales.<\/p>\n<p>Keros expects to distribute 25% of the net cash proceeds from this milestone payment to its stockholders following receipt of the payment.<\/p>\n<p>\n        <strong>About Elritercept <\/strong>\n      <\/p>\n<p>Elritercept is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-\u00df receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. Elritercept is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with MF.<\/p>\n<p>\n        <strong>About Keros Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-\u00df family of proteins. Keros is a leader in understanding the role of the TGF-\u00df family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros\u2019 lead product candidate, rinvatercept, is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. Keros\u2019 most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with MF.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as \u201cexpect,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201celigible\u201d or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros\u2019 expectations regarding the progress of the elritercept program; the expected milestone payment under the global license agreement with Takeda; the expected distribution of net proceeds from such milestone payment to Keros\u2019 stockholders; and the other potential milestone and royalty payments under the global license agreement with Takeda. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros\u2019 limited operating history and historical losses; Keros\u2019 ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros\u2019 dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros\u2019 ability to obtain, maintain and protect its intellectual property; and Keros\u2019 dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.<\/p>\n<p>These and other risks are described more fully in Keros\u2019 filings with the Securities and Exchange Commission (\u201cSEC\u201d), including the \u201cRisk Factors\u201d section of the Company\u2019s Quarterly Report on Form 10-Q, filed with the SEC on August 3, 2026, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Justin Frantz<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M_7krv8rcnwU1jyCTxrYO2kBX2tLl9xmcQ4EgjbLI6kUGjo7wPVv4LM0RkbYFjplUlPclfyf9IxyoBiDm4SVyDAM3idNKoWDz4LTPLjJs9M=\" rel=\"nofollow\" target=\"_blank\">jfrantz@kerostx.com<\/a>\u00a0<br \/>617-221-6042<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTAyNCM3ODY2NTkyIzIxMjU5MzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTY5MWRkYmItMDZmZC00NGIzLTljYzctN2YyODk0ZTZmMDM2LTExMzc1MDQtMjAyNi0wOS0yOS1lbg==\/tiny\/Keros-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) &#8212; Keros Therapeutics, Inc. (\u201cKeros\u201d) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (\u201cTGF-\u00df\u201d) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis (\u201cMF\u201d) and anemia on concurrent ruxolitinib therapy. \u201cThe milestone &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1006560","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) &#8212; Keros Therapeutics, Inc. (\u201cKeros\u201d) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (\u201cTGF-\u00df\u201d) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis (\u201cMF\u201d) and anemia on concurrent ruxolitinib therapy. \u201cThe milestone &hellip; Continue reading &quot;Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-29T14:13:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTAyNCM3ODY2NTkyIzIxMjU5MzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda\",\"datePublished\":\"2026-09-29T14:13:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\\\/\"},\"wordCount\":809,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTAyNCM3ODY2NTkyIzIxMjU5MzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\\\/\",\"name\":\"Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTAyNCM3ODY2NTkyIzIxMjU5MzM=\",\"datePublished\":\"2026-09-29T14:13:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTAyNCM3ODY2NTkyIzIxMjU5MzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTAyNCM3ODY2NTkyIzIxMjU5MzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/","og_locale":"en_US","og_type":"article","og_title":"Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda - Market Newsdesk","og_description":"LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) &#8212; Keros Therapeutics, Inc. (\u201cKeros\u201d) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (\u201cTGF-\u00df\u201d) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis (\u201cMF\u201d) and anemia on concurrent ruxolitinib therapy. \u201cThe milestone &hellip; Continue reading \"Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-29T14:13:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTAyNCM3ODY2NTkyIzIxMjU5MzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda","datePublished":"2026-09-29T14:13:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/"},"wordCount":809,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTAyNCM3ODY2NTkyIzIxMjU5MzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/","name":"Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTAyNCM3ODY2NTkyIzIxMjU5MzM=","datePublished":"2026-09-29T14:13:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTAyNCM3ODY2NTkyIzIxMjU5MzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTAyNCM3ODY2NTkyIzIxMjU5MzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-to-receive-additional-development-milestone-payment-from-partner-takeda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1006560"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006560\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1006560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1006560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1006560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}